Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Shionogi Allies with UK Universities, Bioventures for Drug Discovery
October 26, 2009
- Rasilez May Become Blockbuster: T. Rosenberg, Novartis
October 26, 2009
- Life Science Degrades to 2nd Place in Priority Science and Technology Ranking
October 26, 2009
- Datamonitor Predicts that Acquisition of Solvay Will Have Positive Effects on Abbott
October 26, 2009
- R＆D NEWS IN BRIEF
October 26, 2009
- Nat'l Univ. Hospitals Plans to Start Joint Purchasing in FY2010
October 26, 2009
- Hokkaido Univ. Hospital to Increase Direct Purchase of Drugs
October 26, 2009
- Cravit Remains No. 1 on Both HP, GP Markets: Rep Track Survey
October 26, 2009
- Korosho to Base Requirements for Premium for Generics on Their Volume Dispensed
October 26, 2009
- Otsuka Holdings Receives 2009 Investor in France Award
October 26, 2009
- New Gov't Will Continue to Promote Use of Generics: Mr Isobe
October 26, 2009
- Global Pharmaceutical Market to Grow 4-6% in 2010: IMS Health
October 26, 2009
- Biosimilars to Save 8.1 Billion Euro by 2020 in Germany
October 26, 2009
- BUSINESS NEWS IN BRIEF
October 26, 2009
- Sales of OTC Drugs Increase in Aug. for the First Time in 3 Months: Crecon
October 26, 2009
- Korosho to Stop Use of Add'l ¥85.4 Bil. in FY2009 Supplementary Budget
October 26, 2009
- 4 Medical Devices Recommended for Approval
October 26, 2009
- NHI Price Revision Rate, Policy to Be Proposed by Panel under Health Minister
October 26, 2009
- New Drugs Account for 13% of Total Sales: Novartis
October 19, 2009
- Sandoz's Somatropin Equivalent to Original Product: Mr Nakamichi
October 19, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…